NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
PSNL
Personalis, Inc.
PSNL has a slight edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PSNL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
PSNL's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PSNL PE Valuation
PSNL has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PSNL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PSNL's losses to shrink, with revenue growing.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PSNL on earnings quality, reporting a profit while its opponent remains loss making.
PSNL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.17 | -$0.29 |
| Q2 2026 | -$1.09 | +$0.19 |
| Q1 2026 | -$1.02 | +$0.27 |
| Q4 2025 | -$0.91 | +$0.46 |
| Q3 2025 | -$0.88 | +$0.80 |
| Q2 2025 | -$1.28 | +$0.36 |
| Q1 2025 | -$1.29 | +$0.61 |
| Q4 2024 | -$1.37 | +$0.88 |
PSNL is still losing money, but far less than before: $1.17 per share over the past year, against $2.48 at its worst in late 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PSNL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PSNL on profitability, with a higher operating margin.
PSNL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.6M | +77% |
| Q2 2026 | $22.4M | +30% |
| Q1 2026 | $15.5M | -25% |
| Q4 2025 | $17.3M | +3.2% |
| Q3 2025 | $14.5M | -44% |
| Q2 2025 | $17.2M | -24% |
| Q1 2025 | $20.6M | +5.5% |
| Q4 2024 | $16.8M | -15% |
PSNL's revenue is growing: $26M last quarter, up 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139% | +22 points |
| Q2 2026 | -150% | -24 points |
| Q1 2026 | -208% | -122 points |
| Q4 2025 | -146% | -38 points |
| Q3 2025 | -161% | -105 points |
| Q2 2025 | -127% | -52 points |
| Q1 2025 | -86% | +11 points |
| Q4 2024 | -108% | +14 points |
PSNL's operating margin was −139% last quarter, up 22 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PSNL on cash generation, producing positive trailing cash flow while its opponent burns cash.
PSNL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.1M | -$6.7M |
| Q2 2026 | -$29.6M | -$16.3M |
| Q1 2026 | -$25.7M | -$5.2M |
| Q4 2025 | -$22.3M | -$13.3M |
| Q3 2025 | -$23.4M | -$17M |
| Q2 2025 | -$13.2M | -$2.5M |
| Q1 2025 | -$20.5M | +$45K |
| Q4 2024 | -$9M | +$7.9M |
PSNL has burned cash in almost every quarter: −$108M over the past year, against −$66M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PSNL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PSNL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +1.8M shares |
| 1 year | +21% | +18.5M shares |
| 3 years | +125% | +59.5M shares |
| 5 years | +144% | +63.2M shares |
| Available history | +242% | +75.9M shares |
PSNL has 107M diluted shares, up 21% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PSNL Net Leverage
PSNL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PSNL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 50.9 | Neutral |
PSNL's weekly RSI is 60 (neutral) and its Stochastic is 51 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PSNL PE vs Healthcare Sector
PSNL has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PSNL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.0 | 0.6% below |
| 20 week MA | $15.4 | 2.8% above |
| 50 week MA | $11.2 | 42% above |
| 100 week MA | $8.46 | 87% above |
| 200 week MA | $5.45 | 191% above |
PSNL has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PSNL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.68 | $41.5 | +329% |
| 2021 | $41.5 | $14.4 | -65% |
| 2022 | $14.4 | $1.95 | -86% |
| 2023 | $1.95 | $2.10 | +7.7% |
| 2024 | $2.10 | $5.87 | +180% |
| 2025 | $5.87 | $8.14 | +39% |
| 2026 YTD | $8.14 | $15.9 | +95% |
PSNL has the edge over NVO on returns for 2026, with the stronger performance.